MARKET

CELG

CELG

Celgene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

109.64
-0.77
-0.70%
Opening 12:46 11/14 EST
OPEN
109.95
PREV CLOSE
110.41
HIGH
110.53
LOW
109.52
VOLUME
1.45M
TURNOVER
--
52 WEEK HIGH
110.70
52 WEEK LOW
58.59
MARKET CAP
78.00B
P/E (TTM)
13.68
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CELG and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CELG News

  • Top Ranked Growth Stocks to Buy for November 14th
  • Zacks.2h ago
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.4h ago
  • Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates
  • Zacks.21h ago
  • Editas adds to Celgene collaboration-stoked up move, shares ahead 4%
  • Seeking Alpha - Article.1d ago

More

Industry

Pharmaceuticals
-0.66%
Pharmaceuticals & Medical Research
-0.55%

Hot Stocks

Name
Price
%Change

About CELG

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
More

Webull offers Celgene Corporation (CELG) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.